Business
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Event exploring the escalating threat of emerging infectious diseases Discussion covering...
About this update from Appili Therapeutics Inc Class A
[{"type":"text","content":"Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025\n\n\n\n\n Event exploring the escalating threat of emerging infectious diseases\n \n\n\n\n Discussion covering going-private transaction with Aditxt, strategic growth partner\n \n\n\n HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (NASDAQ: ADTX) (\"Aditxt\") Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4, 2025. The discussion will cover the Company’s recent operational highlights, including $117 million in new federal funding applications, and the status of the going-private transaction with Aditxt.\n \n\n Dr. Cilla will join Aditxt to explore the escalating threat of emerging infectious diseases and highlight the vital role of strategic partnerships in developing innovative treatments and improving global public health. The Aditxt Weekly Update will also provide insights into Appili’s diverse near-to-market portfolio, designed to address critical unmet patient needs.\n \n\n Additionally, the discussion will highlight Appili’s proven track record in securing non-dilutive funding, showcasing $33.2 million in prior government awards and the recent submission of $117 million in new federal funding applications. By leveraging financial support, Appili can strengthen its ability to accelerate the development of new and existing infectious disease treatments aligned with public health priorities.\n \n\n Participants are encouraged to register in advance by\n \n clicking here\n \n . The event will also include a Q&A session, with questions welcomed at\n \n [email protected]\n \n .\n \n\n Appili will join additional Aditxt Weekly Updates throughout the year.\n \n\n\n About Appili Therapeutics\n \n\n\n Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with...